Active Comparator, Euvichol-Plus

Phase 1Biologic

IInternational Vaccine Institute

Active Comparator, Euvichol-Plus is one of 26 biologic programs targeting Hepatitis B. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

Hepatitis BPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 2

Measles Vaccine

GSK

Phase 3

1 3

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

4 4

Hexaxim

Sanofi

Phase 3

1 5

Vemlidy

Gilead

Preclinical

8 6

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

15 7

Henogen HB Vaccine

HHenogen

Phase 3

1 8

Quinvaxem

CCrucell Holland BV

Phase 3

1 9

Nulojix

Bristol-Myers Squibb

Preclinical

1 10

HEPCLUDEX

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Hepatitis B

NCT06800131

Q1 2027

Phase 3Recruiting

Immunogenicity

NCT07304284

Clinical

Trials by Indication[1]

Immunogenicity1 trial

Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus

Recruiting·IInternational Vaccine Institute·Phase 3·NCT07304284·2,824 enrolled

Hepatitis B1 trial

Hepatitis B Vaccine Delivered Trans-dermally by MAP

Not yet recruiting·IInternational Vaccine Institute·Phase 1·NCT06800131·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Active Comparator, Euvichol-Plus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Active Comparator, Euvichol-Plus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Active Comparator, Euvichol-Plus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International Vaccine Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInternational Vaccine Institute

Active Comparator, Euvichol-Plus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Immunogenicity1 trial

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News